Worldwide, heterozygous familial hypercholesterolemia (FH) affects approximately 1 in 250 to 350 individuals. Author James Stein, MD, of the University of Wisconsin School of Medicine and Public Health joins JAMA Deputy Editor Karen Lasser, MD, MPH, to discuss the epidemiology, diagnosis, and treatment of both homozygous and heterozygous FH.
Related Content: